Scientists from the University of Glasgow found that the drug dapagliflozin reduces the risk of heart failure or cardiovascular death, regardless of frailty status.
The research is published in the Annals of Internal Medicine and was conducted by Jawad H. Butt et al.
In the study, the team examined the efficacy of dapagliflozin according to the frailty status of patients.
Data were from the phase 3 randomized Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial.
Patients with symptomatic heart failure with a left ventricular ejection fraction of 40 percent or less and elevated natriuretic peptide were enrolled.
They were assigned to the addition of either once-daily dapagliflozin or placebo to guideline-recommended therapy. Patients were followed for about 18 months.
The team found that regardless of frailty, dapagliflozin reduced the risk of worsening heart failure or heart death. In addition, the frailest patients generally had larger absolute reductions.
The team says that these findings are important considering the common reluctance of doctors to introduce medications to patients that are perceived to be frail
If you care about heart failure, please read studies about diabetes drug that could revolutionize heart failure treatment, and this drug can be a low-cost heart failure treatment
For more information about heart health, please see recent studies about small surgery that can prevent strokes in people with heart issues, and results showing this drug combo can cut risk of stroke and heart attack by half.
Copyright © 2022 Knowridge Science Report. All rights reserved.
